

Maureen D Mayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/33629/publications.pdf>

Version: 2024-02-01

154
papers

19,091
citations

23879

60
h-index

13274

135
g-index

158
all docs

158
docs citations

158
times ranked

15375
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of Perceived Functional Status in Early Systemic Sclerosis: A Prospective Longitudinal Study of an Early Disease Cohort. <i>Arthritis Care and Research</i> , 2023, 75, 1066-1070.	1.5	2
2	Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis Cohorts. <i>Arthritis Care and Research</i> , 2023, 75, 648-656.	1.5	6
3	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	1.5	4
4	Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	2.9	21
5	The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. <i>ACR Open Rheumatology</i> , 2022, 4, 345-351.	0.9	12
6	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. <i>Rheumatology</i> , 2022, 61, 4155-4162.	0.9	8
7	Total Percutaneous Revascularization of the Hand to Treat Refractory Digital Ischemia in Advanced Systemic Sclerosis. <i>JACC: Case Reports</i> , 2022, 4, 161-166.	0.3	1
8	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	0.5	3
9	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	2.9	9
10	47XXY and 47XXX in Scleroderma and Myositis. <i>ACR Open Rheumatology</i> , 2022, 4, 528-533.	0.9	8
11	Genetic Associations of Non-Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2039-2042.e7.	0.3	0
12	False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 56, 152052.	1.6	5
13	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 671-676.	2.9	24
14	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.5	20
15	Exome-Wide Association Analysis Suggests LRP2BP as a Susceptibility Gene for Endothelial Injury in Systemic Sclerosis in the Han Chinese Population. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1254-1263.e6.	0.3	2
16	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	5.2	118
17	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.5	24
18	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3

#	ARTICLE	IF	CITATIONS
19	Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?. <i>Arthritis Research and Therapy</i> , 2021, 23, 259.	1.6	13
20	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
21	Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221352.	0.5	12
22	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	2.9	163
23	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.5	97
24	Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	23
25	Machine learning predicts stem cell transplant response in severe scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1608-1615.	0.5	29
26	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. <i>Scientific Reports</i> , 2020, 10, 1862.	1.6	18
27	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	0.5	7
28	Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 1668-1677.	1.0	16
29	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1371-1378.	0.5	43
30	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	5.8	100
31	Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. <i>Human Molecular Genetics</i> , 2019, 28, 3498-3513.	1.4	65
32	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	0.9	0
33	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2518-2528.	13.9	1,025
34	Predictors of Hand Contracture in Early Systemic Sclerosis and the Effect on Function: A Prospective Study of the GENISOS Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 1597-1604.	1.0	6
35	OP0190...META-ANALYSIS OF IMMUNOCHIP DATA OF FOUR AUTOIMMUNE DISEASES REVEALS NOVEL SINGLE-DISEASE AND CROSS-PHENOTYPE ASSOCIATIONS. , 2019, , .		0
36	Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 311-319.	0.5	81

#	ARTICLE	IF	CITATIONS
37	Associations of Multiple <i>NOTCH4</i> Exonic Variants with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 184-189.	1.0	8
38	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	13.9	417
39	Meta-analysis of ImmunoChip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. <i>Genome Medicine</i> , 2018, 10, 97.	3.6	73
40	KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2018, 45, 1153-1158.	1.0	56
41	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018, 70, 1654-1660.	2.9	10
42	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018, 13, e0189498.	1.1	25
43	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
44	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
45	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	2.9	9
46	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
47	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 799-805.	1.0	25
48	Characterization of the HLA-DR β 1 third hypervariable region amino acid sequence according to charge and parental inheritance in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 46.	1.6	3
49	Longitudinal patterns of pain in patients with diffuse and limited systemic sclerosis: integrating medical, psychological, and social characteristics. <i>Quality of Life Research</i> , 2017, 26, 85-94.	1.5	15
50	Clinical and serological features of systemic sclerosis in a multicenter African American cohort. <i>Medicine (United States)</i> , 2017, 96, e8980.	0.4	78
51	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.0	321
52	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. <i>Arthritis and Rheumatology</i> , 2017, 69, 1871-1878.	2.9	61
53	Epidemiology, Environmental, and Infectious Risk Factors. , 2017, , 11-24.		3
54	Brief Report: HLA-DR β 1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2772-2777.	2.9	15

#	ARTICLE	IF	CITATIONS
55	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754
56	Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1816-1824.	1.0	26
57	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016, 18, 305.	1.6	58
58	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	1.6	18
59	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	2.9	46
60	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.5	41
61	Detection of anti-U3-RNP/fibrillar IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. <i>Immunologic Research</i> , 2016, 64, 483-488.	1.3	12
62	Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. <i>PLoS Medicine</i> , 2016, 13, e1001976.	3.9	150
63	Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3016-3026.	2.9	123
64	Genetics, Epigenetics, and Genomics of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 345-366.	0.8	28
65	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1369-1379.	0.9	21
66	Update on Systemic Sclerosis. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 25.	2.4	9
67	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	1.6	60
68	Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, xv-xvi.	0.8	1
69	Genetics of systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 443-451.	2.8	37
70	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. <i>Autoimmunity</i> , 2015, 48, 542-551.	1.2	29
71	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S131-5.	0.4	24
72	Insights into the genetic basis of systemic sclerosis: immunity in human disease and in mouse models. <i>Advances in Genomics and Genetics</i> , 2014, , 143.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Association of HLA-DPB1 with Scleroderma and Its Clinical Features in Chinese Population. PLoS ONE, 2014, 9, e87363.	1.1	35
74	Association of the HLA-DRB1 with Scleroderma in Chinese Population. PLoS ONE, 2014, 9, e106939.	1.1	29
75	Identification of <i>IL12RB1</i> as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	2.9	29
76	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism, 2014, 44, 55-62.	1.6	69
77	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
78	International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014, 48-49, 60-65.	3.0	170
79	Lack of Association of the CD247 SNP rs2056626 with Systemic Sclerosis in Han Chinese. Open Rheumatology Journal, 2014, 8, 43-45.	0.1	21
80	Genetics of scleroderma: implications for personalized medicine?. BMC Medicine, 2013, 11, 9.	2.3	43
81	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
82	Clinical and serological features of systemic sclerosis in a Chinese cohort. Clinical Rheumatology, 2013, 32, 617-621.	1.0	55
83	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	0.8	104
84	Morphea in Adults and Children Cohort III. JAMA Dermatology, 2013, 149, 1159.	2.0	68
85	Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis. Arthritis and Rheumatism, 2013, 65, 2917-2927.	6.7	39
86	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.5	52
87	What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?. Current Opinion in Rheumatology, 2013, 25, 686-691.	2.0	17
88	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.5	56
89	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.5	30
90	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	1.4	104

#	ARTICLE	IF	CITATIONS
91	Measuring Illness Behavior in Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 585-593.	1.5	8
92	A GWAS follow-up study reveals the association of the <i>IL12RB2</i> gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012, 21, 926-933.	1.4	74
93	Novel identification of the <i>IRF7</i> region as an anticentromere autoantibody propensity locus in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 114-119.	0.5	62
94	The genetics of scleroderma. <i>Current Opinion in Rheumatology</i> , 2012, 24, 677-684.	2.0	28
95	<i>IRF5</i> polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1197-1202.	0.5	72
96	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	1.4	98
97	Epidemiology of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 165-170.	2.0	257
98	Independent Replication and Metaanalysis of Association Studies Establish <i>TNFSF4</i> as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	1.0	35
99	Epidemiology and Environmental Risk Factors. , 2012, , 17-28.		4
100	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S23-9.	0.4	28
101	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.5	394
102	Determinants of Work Disability in Patients with Systemic Sclerosis: A Longitudinal Study of the GENISOS Cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 38-47.	1.6	33
103	Anti-Fibrillar Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis. <i>Journal of Rheumatology</i> , 2011, 38, 1622-1630.	1.0	45
104	A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 3540-3546.	6.7	125
105	Association Study of <i>ITGAM</i> , <i>ITGAX</i> and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	1.0	22
106	Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. <i>Rheumatology</i> , 2011, 50, 335-342.	0.9	29
107	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	1.5	201
108	Separate influences of birth order and gravidity/parity on the development of systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 418-424.	1.5	30

#	ARTICLE	IF	CITATIONS
109	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010, 62, 1772-1778.	1.5	29
110	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	9.4	351
111	Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. <i>Human Molecular Genetics</i> , 2010, 19, 707-719.	1.4	37
112	Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 822-827.	0.5	172
113	Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. <i>Journal of Autoimmunity</i> , 2010, 34, 155-162.	3.0	123
114	Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. <i>Journal of Autoimmunity</i> , 2010, 35, 52-57.	3.0	54
115	Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. <i>Arthritis Research and Therapy</i> , 2010, 12, R166.	1.6	148
116	Association of <i>TNFSF4 (OX40L)</i> polymorphisms with susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 550-555.	0.5	115
117	Association of Interleukin 23 Receptor Polymorphisms with Anti-Topoisomerase-I Positivity and Pulmonary Hypertension in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 2715-2723.	1.0	54
118	Primary Biliary Cirrhosis (PBC), PBC Autoantibodies, and Hepatic Parameter Abnormalities in a Large Population of Systemic Sclerosis Patients. <i>Journal of Rheumatology</i> , 2009, 36, 2250-2256.	1.0	101
119	Clinical and genetic factors predictive of mortality in early systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1403-1411.	6.7	106
120	Polymorphisms in <i>TBX21</i> and <i>STAT4</i> increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. <i>Arthritis and Rheumatism</i> , 2009, 60, 3794-3806.	6.7	98
121	HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: A genome-wide association study in Koreans with replication in North Americans. <i>Arthritis and Rheumatism</i> , 2009, 60, 3807-3814.	6.7	109
122	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. <i>Arthritis and Rheumatism</i> , 2008, 58, 15-25.	6.7	1,918
123	Systemic Sclerosis. , 2008, , 343-362.		20
124	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	2.5	411
125	High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. <i>Blood</i> , 2007, 110, 1388-1396.	0.6	240
126	Genetic factors in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S5.	1.6	33

#	ARTICLE	IF	CITATIONS
127	Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. <i>Arthritis and Rheumatism</i> , 2007, 57, 318-326.	6.7	161
128	Clinical, immunologic, and genetic features of familial systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2031-2037.	6.7	32
129	Disease and symptom burden in systemic sclerosis: a patient perspective. <i>Journal of Rheumatology</i> , 2007, 34, 1718-26.	1.0	77
130	Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. <i>Arthritis and Rheumatism</i> , 2006, 54, 1961-1973.	6.7	156
131	Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3661-3669.	6.7	100
132	Association of the PTPN22 R620W polymorphism with anti-topoisomerase and anticentromere antibody-positive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3945-3953.	6.7	99
133	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. <i>New England Journal of Medicine</i> , 2006, 354, 2655-2666.	13.9	1,421
134	Risk of malignancy in scleroderma: A population-based cohort study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2415-2424.	6.7	113
135	Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. <i>American Journal of Medicine</i> , 2005, 118, 907-911.	0.6	21
136	Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 553-557.	6.7	30
137	Endothelin and endothelin receptor antagonists in systemic rheumatic disease. <i>Arthritis and Rheumatism</i> , 2003, 48, 1190-1199.	6.7	124
138	Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. <i>Arthritis and Rheumatism</i> , 2003, 48, 2246-2255.	6.7	809
139	Scleroderma epidemiology. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 239-254.	0.8	264
140	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
141	Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. <i>Arthritis and Rheumatism</i> , 2001, 44, 1359-1362.	6.7	243
142	Recombinant Human Relaxin in the Treatment of Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 132, 871.	2.0	220
143	Approaches for identifying and defining environmentally associated rheumatic disorders. <i>Arthritis and Rheumatism</i> , 2000, 43, 243.	6.7	82
144	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252

#	ARTICLE	IF	CITATIONS
145	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
146	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
147	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998, 41, 670-677.	6.7	175
148	Racial differences in scleroderma among women in Michigan. <i>Arthritis and Rheumatism</i> , 1997, 40, 734-742.	6.7	155
149	SCLERODERMA EPIDEMIOLOGY. <i>Rheumatic Disease Clinics of North America</i> , 1996, 22, 751-764.	0.8	48
150	Familial aggregation of primary Raynaud's disease. <i>Arthritis and Rheumatism</i> , 1996, 39, 1189-1191.	6.7	93
151	Cold-induced potentiation of $\hat{I}\pm 2$ -adrenergic vasoconstriction in primary raynaud's disease. <i>Arthritis and Rheumatism</i> , 1993, 36, 685-690.	6.7	48
152	Increased $\hat{I}\pm$ -Adrenergic responsiveness in idiopathic raynaud's disease. <i>Arthritis and Rheumatism</i> , 1989, 32, 61-65.	6.7	68
153	Stem cell transplantation for systemic sclerosis. <i>The Cochrane Library</i> , 0, , .	1.5	1
154	Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7